Marisa Wexler, MS,  senior science writer—

Corcept Therapeutics is on track to ask the U.S. Food and Drug Administration (FDA) to approve the investigational therapy relacorilant to treat Cushing’s syndrome by the middle of next year, the company announced. Cushing’s syndrome is characterized by excessive levels of the stress hormone cortisol, which causes a range of…

Xeris Pharmaceuticals has selected the specialty pharmacy PANTHERx Rare to distribute Recorlev (levoketoconazole), the company’s therapy that was recently approved to treat adults with endogenous Cushing’s syndrome in whom surgery is not possible or not effective. “PANTHERx is proud to partner with Xeris to address the needs of adults…

Sparrow Pharmaceuticals is gearing up for the start of a Phase 2 trial that will assess the safety and effectiveness of the company’s experimental medicine SPI-62 in people with Cushing’s disease. The U.S. Food and Drug Administration has cleared Sparrow’s investigational new drug application (IND), giving the company…

In people with Cushing’s disease, the activity of an enzyme that breaks down vitamin D is altered, which may affect the effectiveness of vitamin D dietary supplements, according to a new study. The study, “Assessment of Vitamin D Metabolism in Patients with Cushing’s Disease in Response…

The desmopressin stimulation test can be useful to diagnose Cushing’s during pregnancy, a time when its identification may be particularly challenging due to the hormonal changes these women experience, a new case report says. The report, “Desmopressin Stimulation Test in a Pregnant Patient with Cushing’s Disease,” was published…

At an upcoming conference offered by the University of Pennsylvania (Penn), experts will share the latest approaches and techniques for diagnosing and treating Cushing’s disease and other conditions caused by tumors in the pituitary gland. The “4th Pituitary Update” conference will run from 7:45 a.m. to 4 p.m. ET…

A newly discovered mutation in a gene called USP8 may contribute to the development of pituitary tumors, which are the underlying cause Cushing’s disease, researchers reported, describing the mutation. Their work also linked tumors with mutations to more aggressive disease than those without mutations. The study, “Genetic…

Analyzing small amounts of tumor DNA that end up in the bloodstream could be useful for assessing the course of Cushing’s syndrome in patients whose disease is caused by a hormone-producing tumor, a new report illustrates. In the case of a 45-year-old man in France, DNA changes “were well correlated…

People with Cushing’s disease who are treated with Isturisa (osilodrostat) should be monitored for the possibility of developing adrenal insufficiency, a report highlights. The case report, “Osilodrostat in Cushing’s disease: The risk of delayed adrenal insufficiency should be carefully monitored,” was published in the journal…

Thyrotoxicosis, or abnormally high levels of thyroid hormones in the body, is a rare complication that can occur in people with Cushing’s disease who undergo tumor-removal surgery, a new report highlights. The study, “Management of thyrotoxicosis occurring after surgery for Cushing’s disease: a case series,” was…